NCT05682846

Optimization of Serum Phosphorus Level and Weaning From Mechanical Ventilation

Impact of Serum Phosphorus Level Optimization on Weaning From Mechanical Ventilation in Adult ICU Patients

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 124 (actual)
• Sponsor: Alexandria University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to test the impact of serum phosphorus level optimization on weaning from mechanical ventilation in adult ICU patients in Alexandria University Hospitals. The main questions it aims to answer are: * Does serum phosphorus level optimization affect the duration of mechanical ventilation? * Is serum phosphorus level optimization associated with successful weaning from mechanical ventilation? In critically ill patients, phosphorus supplementation is done using Sodium glycerophosphate pentahydrate solution.

Detailed description

Investigators will document patients' data in terms of independent variables and will randomly allocate the participants into one of the two study groups mentioned below. * Control group, defined by maintaining serum phosphorus level at ≥ 2.5 and \< 3.5 mg/dL. * Intervention group, defined by optimization of serum phosphorus P to ≥ 3.5 and ≤ 4.5 mg/dL (Average 4mg/dL). Regression and comparative statistics will be used to determine whether the optimum serum phosphorus level offers a benefit in terms of the duration of mechanical ventilation and the success of weaning from mechanical ventilation.

Conditions

• Mechanical Ventilation

Interventions

Type	Name	Description
DRUG	Sodium glycerophosphate pentahydrate solution	Glycophos is a 20 ml vial of Sodium glycerophosphate pentahydrate containing 1 mmol glycerophosphate and 2 mmol sodium per ml

Timeline

• Start date: 2022-05-01
• Primary completion: 2023-02-28
• Completion: 2023-02-28
• First posted: 2023-01-12
• Last updated: 2023-05-19

Locations

1 site across 1 country: Egypt